ATE506060T1 - Verfahren zur bereitstellung einer pirfenidontherapie an einem patienten - Google Patents

Verfahren zur bereitstellung einer pirfenidontherapie an einem patienten

Info

Publication number
ATE506060T1
ATE506060T1 AT07865831T AT07865831T ATE506060T1 AT E506060 T1 ATE506060 T1 AT E506060T1 AT 07865831 T AT07865831 T AT 07865831T AT 07865831 T AT07865831 T AT 07865831T AT E506060 T1 ATE506060 T1 AT E506060T1
Authority
AT
Austria
Prior art keywords
patient
pirfenidone therapy
pirfenidone
discloses
adverse events
Prior art date
Application number
AT07865831T
Other languages
German (de)
English (en)
Inventor
Williamson Ziegler Bradford
Original Assignee
Intermune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39259551&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE506060(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Intermune Inc filed Critical Intermune Inc
Application granted granted Critical
Publication of ATE506060T1 publication Critical patent/ATE506060T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/03—Containers specially adapted for medical or pharmaceutical purposes for pills or tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/03—Containers specially adapted for medical or pharmaceutical purposes for pills or tablets
    • A61J1/035—Blister-type containers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J2205/00—General identification or selection means
    • A61J2205/50—General identification or selection means using icons or symbolic figures, e.g. by a graphical representation symbolising the type of pathology or the organ by an image

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Pyridine Compounds (AREA)
AT07865831T 2006-12-18 2007-12-18 Verfahren zur bereitstellung einer pirfenidontherapie an einem patienten ATE506060T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87059306P 2006-12-18 2006-12-18
PCT/US2007/087988 WO2008077068A1 (en) 2006-12-18 2007-12-18 Method of providing pirfenidone therapy to a patient

Publications (1)

Publication Number Publication Date
ATE506060T1 true ATE506060T1 (de) 2011-05-15

Family

ID=39259551

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07865831T ATE506060T1 (de) 2006-12-18 2007-12-18 Verfahren zur bereitstellung einer pirfenidontherapie an einem patienten

Country Status (14)

Country Link
US (9) US7767700B2 (enExample)
EP (4) EP3053580B1 (enExample)
JP (1) JP2010513320A (enExample)
AT (1) ATE506060T1 (enExample)
CA (1) CA2667654C (enExample)
CY (1) CY1111699T1 (enExample)
DE (1) DE602007014113D1 (enExample)
DK (1) DK2124945T3 (enExample)
ES (3) ES2581844T3 (enExample)
MX (1) MX2009006526A (enExample)
PL (2) PL3053580T3 (enExample)
PT (1) PT2124945E (enExample)
SI (1) SI2124945T1 (enExample)
WO (1) WO2008077068A1 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2009006526A (es) 2006-12-18 2009-06-30 Intermune Inc Metodo para suministrar terapia con pirfenidona a un paciente.
AU2012205256B2 (en) * 2008-11-10 2015-05-28 Intermune, Inc. Pirfenidone Treatment for Patients with Atypical Liver Function
US7566729B1 (en) 2008-11-10 2009-07-28 Intermune, Inc. Modifying pirfenidone treatment for patients with atypical liver function
US7635707B1 (en) * 2008-11-10 2009-12-22 Intermune, Inc. Pirfenidone treatment for patients with atypical liver function
AP2011005824A0 (en) * 2009-01-26 2011-08-31 Intermune Inc Methods for treating acute myocardial infarctions and associated disorders.
US7816383B1 (en) 2009-12-04 2010-10-19 Intermune, Inc. Methods of administering pirfenidone therapy
US8084475B2 (en) 2009-12-04 2011-12-27 Intermune, Inc. Pirfenidone therapy and inducers of cytochrome P450
JP6021117B2 (ja) 2011-01-31 2016-11-02 ジェノア ファーマシューティカルズ，インク． エアロゾルのピルフェニドンおよびピリドンアナログの化合物、および、その使用
US10105356B2 (en) 2011-01-31 2018-10-23 Avalyn Pharma Inc. Aerosol pirfenidone and pyridone analog compounds and uses thereof
MX2011007675A (es) * 2011-07-19 2012-07-11 Cell Therapy And Technology S A De C V Procedimiento para la fabricacion de una composicion farmaceutica en forma de tabletas de liberacion prolongada conteniendo pirfenidona y su aplicacion en la regresion de la insuficiencia renal cronica, contractura capsular mamaria y fibrosis hepatica humanas.
CA2819967C (en) 2012-08-31 2016-03-22 Intermune, Inc. Use of pirfenidone concomitantly with ciprofloxacin
HK1220133A1 (zh) 2013-03-15 2017-04-28 Intermune, Inc. 改善微血管完整性的方法
USD731783S1 (en) 2014-04-16 2015-06-16 Abbvie Inc. Template for a prescription medicine container
USD731782S1 (en) 2013-10-07 2015-06-16 Abbvie Inc. Template for a prescription medicine container
USD731171S1 (en) 2013-10-07 2015-06-09 Abbvie Inc. Template for a prescription medicine container
EP4491180A1 (en) 2014-01-10 2025-01-15 Avalyn Pharma Inc. Aerosol pirfenidone and pyridone analog compounds and uses thereof
ES2863700T3 (es) * 2016-03-22 2021-10-11 Mayo Found Medical Education & Res Uso de inhibidores de ácido graso sintasa para tratar la fibrosis
CA2937365C (en) 2016-03-29 2018-09-18 F. Hoffmann-La Roche Ag Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same
CA3108048A1 (en) 2017-07-31 2019-02-07 Washington University Pirfenidone derivatives for modulation of b lymphocyte activity and organ protection
USD930973S1 (en) 2018-03-22 2021-09-21 Abbvie Inc. Child-resistant medication container
US11052021B2 (en) 2018-03-22 2021-07-06 Abbvie Inc. Medicine container, method of assembling the container, and method of dispensing the medicine from the container
USD930974S1 (en) 2018-03-22 2021-09-21 Abbvie Inc. Child-resistant medication container
USD882243S1 (en) 2018-03-26 2020-04-28 Abbvie Inc. Child-resistant medication container assembly
CN112638413A (zh) * 2018-07-27 2021-04-09 艾慕恩治疗公司 口服免疫治疗单位剂量分配系统和方法
EP4069227A1 (en) 2019-12-04 2022-10-12 Idorsia Pharmaceuticals Ltd Combination of an azetidine lpa1 receptor antagonist with pirfenidone and/or nintedanib for use in the treatment of fibrotic diseases
GB2589635B (en) * 2019-12-06 2021-12-01 Merxin Ltd Elongate form medicament carrier and medicament dispenser
CN117042738A (zh) * 2021-03-17 2023-11-10 埃科特莱茵药品有限公司 药物剂量系统
EP4486326A1 (en) 2022-02-28 2025-01-08 Nuformix Technologies Limited Compositions and methods for treatment of idiopathic pulmonary fibrosis

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US695044A (en) * 1901-12-28 1902-03-11 Albert E Gibson Non-refillable bottle.
SE9502370D0 (sv) 1995-06-30 1995-06-30 Astra Ab Blister pack, especially for drugs, as well as method and device in manufacturing the same
US6956044B1 (en) * 2000-02-21 2005-10-18 Margolin Solomon B Compositions and methods for treatment of epilepsy
DE60234812D1 (de) * 2001-01-29 2010-02-04 Shionogi & Co Arzneipräparat, das als wirkstoff 5-methyl-1-phenyl-2-(1h)-pyridon enthält
JP2006502152A (ja) * 2002-08-28 2006-01-19 インターミューン インコーポレイテッド 線維性疾患治療用の併用療法
US7413749B2 (en) * 2003-03-11 2008-08-19 Purdue Pharma L.P. Titration dosing regimen for controlled release tramadol
CN101039957A (zh) * 2003-05-16 2007-09-19 因特缪恩公司 合成的趋化因子受体配体及其使用方法
WO2004103296A2 (en) * 2003-05-16 2004-12-02 Intermune, Inc. Methods of treating idiopathic pulmonary fibrosis
US20080025986A1 (en) * 2003-06-06 2008-01-31 Ozes Osman N Methods of Treating Tnf-Mediated Disorders
US20070053877A1 (en) * 2003-08-21 2007-03-08 Intermune, Inc. Methods of treating idiopathic pulmonary fibrosis
US7407973B2 (en) * 2003-10-24 2008-08-05 Intermune, Inc. Use of pirfenidone in therapeutic regimens
GEP20105124B (en) * 2005-07-25 2010-11-25 Array Biopharma Inc Novel macrocyclic inhibitors of hepatitis c virus replication
NZ591443A (en) 2005-09-22 2013-04-26 Intermune Inc Granule formation of pirfenidone and pharmaceutically acceptable excipients
US20070203202A1 (en) * 2005-12-02 2007-08-30 Robinson Cynthia Y Methods of reducing adverse events associated with pirfenidone therapy
US20080003635A1 (en) * 2006-06-12 2008-01-03 Intermune, Inc. High Throughput Collagen Synthesis Assay
EP2036555B1 (en) * 2006-06-15 2011-11-16 Shanghai Genomics, Inc. The use of pyridone derivatives for preventing and treating radiation injury of lungs
KR20090024834A (ko) * 2006-07-05 2009-03-09 인터뮨, 인크. Ｃ형 간염 바이러스 복제의 신규 억제제
MX2009006526A (es) 2006-12-18 2009-06-30 Intermune Inc Metodo para suministrar terapia con pirfenidona a un paciente.
US20080287508A1 (en) * 2007-05-18 2008-11-20 Intermune, Inc. Altering pharmacokinetics of pirfenidone therapy
US8178091B2 (en) * 2007-05-21 2012-05-15 University Of Washington Compositions and methods for the treatment of respiratory disorders

Also Published As

Publication number Publication date
EP2124945A1 (en) 2009-12-02
EP2124945B1 (en) 2011-04-20
EP2471534A1 (en) 2012-07-04
MX2009006526A (es) 2009-06-30
EP2338489B1 (en) 2016-04-27
US20180140588A1 (en) 2018-05-24
US20090197923A1 (en) 2009-08-06
CA2667654C (en) 2016-12-13
US7696236B2 (en) 2010-04-13
US20200113884A1 (en) 2020-04-16
US20190247380A1 (en) 2019-08-15
PL2124945T3 (pl) 2011-09-30
US20190000821A1 (en) 2019-01-03
ES2395396T3 (es) 2013-02-12
US20160324842A1 (en) 2016-11-10
PT2124945E (pt) 2011-07-01
DE602007014113D1 (de) 2011-06-01
CA2667654A1 (en) 2008-06-26
HK1133584A1 (en) 2010-04-01
US20080194644A1 (en) 2008-08-14
HK1153647A1 (en) 2012-04-05
US20130220871A1 (en) 2013-08-29
DK2124945T3 (da) 2011-08-01
JP2010513320A (ja) 2010-04-30
SI2124945T1 (sl) 2011-08-31
ES2581844T3 (es) 2016-09-07
ES2882956T3 (es) 2021-12-03
US7767700B2 (en) 2010-08-03
US8420674B2 (en) 2013-04-16
EP3053580A1 (en) 2016-08-10
PL3053580T3 (pl) 2021-12-20
CY1111699T1 (el) 2015-10-07
US20100324097A1 (en) 2010-12-23
EP2338489A1 (en) 2011-06-29
EP3053580B1 (en) 2021-06-30
WO2008077068A1 (en) 2008-06-26

Similar Documents

Publication Publication Date Title
ATE506060T1 (de) Verfahren zur bereitstellung einer pirfenidontherapie an einem patienten
MX2020004075A (es) Composiciones y metodos que comprenden bupropion o compuestos relacionados y dextrometorfano.
CA3252166A1 (en) Screening method for selected amino lipid-containing compositions
WO2008144241A3 (en) Altering pharmacokinetics of pirfenidone therapy
CL2014000506A1 (es) Sal de ansolvato de noribogaina; composicion que la comprende; polimormo cristalino de solvato de clorhidrato de noribogaina; polimorfo cristalino de sal de fosfato de noribogaina; metodo para tratar dolor nocioceptivo en ausencia de tratamiento de dependencia o abuso de farmacos o de terapia concomitante de analgesico opiaceo.
MX350745B (es) El uso de un compuesto de carbamoilo para el tratamiento del sindrome de fibromialgia.
WO2012071369A3 (en) A non-retinoid rbp4 antagonist for treatment of age-related macular degeneration and stargardt disease
GEP20186880B (en) 2-amino-3, 5, 5-trifluoro-3, 4, 5, 6-tetrahydropyridines as bace1 inhibitors for treatment of alzheimer's disease
IL213112A (en) Nemphen hydrochloride dihydrate
WO2012002687A3 (en) Methods for treating bipolar disorder
WO2010017368A3 (en) Methods and compositions for treating anxiety
WO2013085849A3 (en) Sulfate esters of noribogaine
WO2012158230A3 (en) Dental implant system with separable drive and method
WO2016168553A8 (en) Deuterated obeticholic acid
PH12014500381A1 (en) Therapeutic methods
WO2013083826A3 (en) Glp-1 agonists
WO2012002773A3 (en) Phenylcarbamate compound and muscle relaxant containing the same
WO2011131370A8 (en) Melt-granulated fingolimod
IL289731A (en) Methods for treating or preventing asthma by administering an antagonist to il-4r
AU2018333954A1 (en) Methods and compositions to inhibit dependence on opioids
CY1120920T1 (el) Συνθεσεις υψηλης δοσης βουπρενορφινης και χρηση ως αναλγητικο
EP2415753A4 (en) IMPROVED METHOD FOR PREPARING A DIPEPTIDYL-PEPTIDASE IV HEMMER AND AN INTERMEDIATE PRODUCT THEREOF
WO2014028397A3 (en) Laquinimod for treatment of gaba mediated disorders
WO2012119006A3 (en) Derivatives of pyrazole-substituted amino-heteroaryl compounds
MX2011012538A (es) Terapia de combinacion para el tratamiento del mieloma multiple.